Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, and emerging pathogens.
Limitations of traditional vaccine platforms have sparked the discovery and development of novel vaccine technologies. The need for a new generation of vaccines has led to a concurrent requirement for improved adjuvants and delivery systems. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well suited to address existing technology limitations. These new technologies can address unmet medical needs, such as for vaccines that involve antigens that are difficult to manufacture or for novel pathogens for which rapid development is critical. The introduction of monoclonal antibodies, recombinant DNA, and protein engineering techniques has facilitated a rather rapid increase in the knowledge of pathogenic organisms, as well as protective antigens at the molecular level. This provides the basis for the development of a new generation of vaccines. Some of these vaccines contain purified immunogens, or even isolated epitopes, identified and prepared by molecular biological techniques. The efforts to find better delivery systems and better adjuvants accompany the research on vaccines.
With recent advances in medicinal chemistry, immunology, pharmacology, and nanotechnology, a variety of new adjuvants, delivery systems, and formulations for subunit vaccines are currently in development. The vaccine composition also strongly depends on the immunization route, thus intensive efforts are also concentrated on the development of vaccines that can be administered orally, intranasally, intradermally, etc., to avoid the disadvantageous of the classical injectable pathway.
This Research Topic will focus on the current status of vaccines, novel delivery methods, adjuvants, and platform technologies that can be applied to a large number of recalcitrant and emerging pathogens.
We welcome the submissions of Original Research, Review, Perspective, and Clinical trials articles covering, but not limited to, the following topics:
• Immunogenicity and proof of concept
• Antigen delivery systems
• Targeted delivery of antigens to immune cells
• Adjuvants for human use
• Liposomes in vaccine delivery
• Polymers as delivery platforms for vaccines
• Mechanism of action of novel adjuvants
• Vaccine formulations for parasitic diseases
• Preclinical trial related to the development of vaccines against parasites
• Human Clinical trial related to the development of vaccines against parasites
• Immune correlates of protection against parasites
Keywords:
Apicomplexa, Malaria, Toxoplasma, Theileria, Babesia, Leismania, Helminths, Neglected tropical diseases, Vaccines
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, and emerging pathogens.
Limitations of traditional vaccine platforms have sparked the discovery and development of novel vaccine technologies. The need for a new generation of vaccines has led to a concurrent requirement for improved adjuvants and delivery systems. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well suited to address existing technology limitations. These new technologies can address unmet medical needs, such as for vaccines that involve antigens that are difficult to manufacture or for novel pathogens for which rapid development is critical. The introduction of monoclonal antibodies, recombinant DNA, and protein engineering techniques has facilitated a rather rapid increase in the knowledge of pathogenic organisms, as well as protective antigens at the molecular level. This provides the basis for the development of a new generation of vaccines. Some of these vaccines contain purified immunogens, or even isolated epitopes, identified and prepared by molecular biological techniques. The efforts to find better delivery systems and better adjuvants accompany the research on vaccines.
With recent advances in medicinal chemistry, immunology, pharmacology, and nanotechnology, a variety of new adjuvants, delivery systems, and formulations for subunit vaccines are currently in development. The vaccine composition also strongly depends on the immunization route, thus intensive efforts are also concentrated on the development of vaccines that can be administered orally, intranasally, intradermally, etc., to avoid the disadvantageous of the classical injectable pathway.
This Research Topic will focus on the current status of vaccines, novel delivery methods, adjuvants, and platform technologies that can be applied to a large number of recalcitrant and emerging pathogens.
We welcome the submissions of Original Research, Review, Perspective, and Clinical trials articles covering, but not limited to, the following topics:
• Immunogenicity and proof of concept
• Antigen delivery systems
• Targeted delivery of antigens to immune cells
• Adjuvants for human use
• Liposomes in vaccine delivery
• Polymers as delivery platforms for vaccines
• Mechanism of action of novel adjuvants
• Vaccine formulations for parasitic diseases
• Preclinical trial related to the development of vaccines against parasites
• Human Clinical trial related to the development of vaccines against parasites
• Immune correlates of protection against parasites
Keywords:
Apicomplexa, Malaria, Toxoplasma, Theileria, Babesia, Leismania, Helminths, Neglected tropical diseases, Vaccines
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.